LncRNA expression data from BRCA drug-sensitive and drug-resistant cell lines

Worldwide, breast cancer (BRCA) is the most common malignant tumor in women. Adriamycin (ADR) is considered one of the most effective agents for the treatment of BRCA, but its efficacy as a curative agent is compromised by intrinsic resistance and the acquisition of multidrug resistance characteristics during chemotherapy. The underlying mechanisms resulting in ADR resistance in BRCA remain poorly understood. Long non-coding RNA (lncRNA) are abnormally expressed in many cancers and are highly involved in its pathogenesis, including drug resistance. In order to systematically study the role of lncRNA in the resistance of BRCA cells to ADR, we used lncRNA expression microarray to establish gene expression profiles of ADR resistant cell lines and ADR sensitive cell lines. The ADR sensitive cell line MCF-7 and the ADR resistant cell line MCF-7/ADR were used for RNA extraction and hybridization on microarrays. We are trying to study the expression profile of lncRNA in BRCA cell lines and find the key factors that mediate breast cancer drug resistance.